The expression of key factors in Notch signaling, including MAML3, PSEN2, and the downstream target gene Hes1, was significantly increased after sorafenib treatment in three AML patients carrying the FLT3-ITD mutation (Fig. 1a). This evidence concerns the gene MAML3 and acute myeloid leukemia.